

GUIDED THERAPEUTICS INC  
Form 8-K  
October 04, 2011

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event) October 4, 2011; (October 4, 2011)

**GUIDED THERAPEUTICS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

**0-22179**

**58-2029543**

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)  
Incorporation)

**5835 Peachtree Corners East, Suite D**  
**30092**  
**Norcross, Georgia**  
(Zip Code)  
(Address of Principal Executive Offices)

Registrant's Telephone Number, Including Area Code: **(770) 242-8723**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 7.01 (Regulation FD Disclosure)**

On October 4, 2011, the registrant publicly issued a press release announcing that its LuViva™ Advanced Cervical Scan was included in a review by a division of National Health Service in the United Kingdom of new adjunctive colposcopy technologies, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

The following exhibit is furnished with this report:

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
<u>99.1</u>	Press Release dated October 4, 2011

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GUIDED THERAPEUTICS, INC**

By: /s/ MARK L. FAUPEL  
Mark L. Faupel, Ph.D.  
CEO & President

Date: October 4, 2011



